BIOMAT Database Logo BIOMAT Database Logo

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. 1997

D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
National Cancer Institute, Bethesda, Maryland 20815, and the University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Preclinical studies have demonstrated that recombinant IFN-alpha (rIFN-alpha) can enhance the tumor associated glycoprotein 72 (TAG-72) on tumors. To determine whether rIFN-alpha could enhance TAG-72 expression in vivo in patients, 15 women with breast cancer were randomized to receive daily injections of rIFN-alpha (3 x 10(6) units/m2 for 14 days) beginning on day 1 (group 1 = 7 patients) or on day 6 (group 2 = 8 patients). On day 3, all patients received a 10-20-mCi tracer dose of 131I-CC49, a high-affinity murine monoclonal antibody reactive against TAG-72, followed by a therapy dose of 60-75 mCi/m2 of 131I-CC49 on day 6. Whole body and single-photon emission computed tomography scans along with whole blood pharmacokinetics were performed following tracer and treatment phases. Hematological toxicity was considerable; reversible grade 3-4 neutropenia and thrombocytopenia was observed in 12 of 15 patients. Twelve of 14 patients tested developed human antimouse antibodies 3-6 weeks after treatment. For group 1 patients, whole blood residence time increased significantly between that predicted from the tracer doses and therapy doses (42.6 +/- 4.7 versus 51.5 +/- 4.8 h, respectively; P < 0.01). The calculated radiation absorbed dose to red marrow from therapy compared to tracer activity was also significantly higher for this group (1.25 +/- 0.35 versus 1. 07 +/- 0.26 cGy/mCi; P < 0.05). Treatment with rIFN-alpha was found to enhance TAG-72 expression in tumors from patients receiving rIFN-alpha (group 1) by 46 +/- 19% (P < 0.05) compared to only 1.3 +/- 0.95% in patients not initially receiving IFN (group 2). The uptake of CC49 in tumors was also significantly increased in rIFN-alpha-treated patients. One partial and two minor tumor responses were seen. In summary, rIFN-alpha treatment altered the pharmacokinetics and tumor uptake of 131I-CC49 in patients at the expense of increased toxicity.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
October 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
March 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
February 1994, Cancer,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
December 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
March 2005, European journal of nuclear medicine and molecular imaging,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
August 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
November 1996, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
December 1995, Cancer research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
February 1993, Cancer research,
D J Macey, and E J Grant, and L Kasi, and M G Rosenblum, and H Z Zhang, and R L Katz, and P T Rieger, and D LeBherz, and M South, and J W Greiner, and J Schlom, and D A Podoloff, and J L Murray
Biodistribution and pharmacokinetics of 131I-labeled LEX 032, a recombinant hybrid of antichymotrypsin.
May 1997, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!